Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

245.37USD
24 Feb 2017
Change (% chg)

$-1.66 (-0.67%)
Prev Close
$247.03
Open
$246.11
Day's High
$246.42
Day's Low
$243.98
Volume
415,950
Avg. Vol
1,058,004
52-wk High
$301.12
52-wk Low
$184.58

Latest Key Developments (Source: Significant Developments)

Allergan receives FDA clearance for a new surgical treatment for refractory glaucoma
Tuesday, 22 Nov 2016 07:35am EST 

Allergan Plc : Allergan receives FDA clearance for the xen® gel stent, a new surgical treatment for refractory glaucoma . Allergan Plc - Allergan plans to launch xen in U.S. In early 2017 .Allergan Plc - Allergan plans to launch xen glaucoma treatment system in U.S. in early 2017.  Full Article

Allergan received an additional approval from Health Canada for fibristal
Monday, 21 Nov 2016 08:00am EST 

Allergan Plc :Allergan Plc - received an additional approval from Health Canada for fibristal.  Full Article

Urogen Pharma announces agreement to license RTGEL for use with Neurotoxins to Allergan
Friday, 14 Oct 2016 07:00am EDT 

Allergan Plc : Press release - Urogen Pharma announces agreement to license RTGEL™ for use with Neurotoxins to Allergan .Urogen Pharma - Allergan to make upfront payment of $17.5 million, as well as potential development and commercial milestones and royalties on net sales.  Full Article

Allergan says FDA accepts supplemental new drug application for avycaz
Tuesday, 11 Oct 2016 08:01am EDT 

Allergan Plc: FDA accepts supplemental new drug application (SNDA) for avycaz® (ceftazidime and avibactam) . Allergan plc - FDA is expected to take action on filing in q1 of 2017. . Allergan - application seeks to expand avycaz label to include phase 3 clinical data for treatment of complicated urinary tract infections .Allergan plc - application included results from a phase 3 study evaluating efficacy and safety of avycaz for treatment of patients with cuti.  Full Article

Allergan Plc enters licensing agreement with Astrazeneca for worldwide rights to Medi2070
Monday, 3 Oct 2016 02:00am EDT 

Allergan Plc : In addition, Allergan may make potential payments to astrazeneca of up to $1.27 billion, payable over a period of up to 15 years . Says Medimmune will continue ongoing medi2070 phase iia study in crohn's disease to completion . Potential payments include launch milestone payments of up to $435 million and sales-based milestone payments of $725 million . Allergan plc enters into licensing agreement with astrazeneca to obtain worldwide rights to medi2070 inflammatory disorder development program . Allergan will make an upfront payment to astrazeneca of $250 million for exclusive, worldwide license to develop and commercialize medi2070 .Says medimmune will transition phase IIb study in crohn's disease to allergan for completion.  Full Article

Allergan says egregious price hikes by "outlier" companies hurting venture capital investment
Tuesday, 6 Sep 2016 11:14am EDT 

Allergan CEO, in interview: Says Allergan aims to limit annual price increases of branded therapeutic drugs to low to mid single digit percentage range, slightly above current annual rate of inflation . Says Allergan's planned price increase limits would be similar to company's price increases seen in 2016, and should follow in 2017, beyond . Says Hillary Clinton's plan for oversight panels to monitor, punish drugmakers that impose unreasonable price increases on life-saving drugs impractical in free market system . Says Clinton's proposal for emergency imports of drugs to ease drug shortages, prices could subject U.S. public to lower safety standards . Says publicity from "egregious" price increases of other companies have caused shrinkage of venture capital investment in new drugs .Says "outlier" companies that have drawn criticism for price hikes are endangering overall industry research and development.  Full Article

Allergan acquires gene therapy company Retrosense Therapeutics
Tuesday, 6 Sep 2016 08:00am EDT 

Allergan Plc : Allergan Acquires Gene Therapy Company Retrosense Therapeutics Adding First-In-Class technology to company's innovative eye care pipeline . Says under terms of transaction, Allergan has paid Retrosense a $60 million upfront payment . Says also has agreed to potential regulatory and commercialization milestone payments related to rst-001 .Says acquired substantially all of assets of Retrosense in an all-cash transaction.  Full Article

Allergan and Adamas enter settlement with Amneal Pharmaceuticals
Wednesday, 31 Aug 2016 08:00am EDT 

Allergan Plc : Allergan and Adamas announce settlement with Amneal related to namzaric patent litigation . Adamas will grant amneal a license to market generic versions of namzaric beginning on January 1, 2025 . Other terms of settlement were not disclosed . Under certain circumstances, amneal has an option to launch an authorized generic version of namzaric beginning on January 1, 2026 . Settlement provides additional clarity for patent-protected life of namzaric .Alternatively, under certain circumstances, amneal has option to launch authorized generic version of namzaric beginning on January 1, 2026.  Full Article

Allergan to acquire eye care company Forsight Vision5
Thursday, 11 Aug 2016 08:00am EDT 

Allergan PLC : Allergan to acquire eye care company Forsight Vision5 adding Peri-Ocular Ring Technology to company's leading portfolio of innovative eye health products . Under terms of agreement, Allergan will acquire Forsight Vision5 for a $95 million upfront payment and a launch milestone payment .Transaction is expected to be completed within 60 days.  Full Article

Allergan Equico reports 9.9 pct stake in Teva Pharmaceutical
Monday, 8 Aug 2016 06:15pm EDT 

Allergan :Reports a stake of 9.9 pct in Teva Pharmaceutical Industries Ltd as of July 27, 2016 - SEC filing.  Full Article

More From Around the Web

BRIEF-Allergan says Goldman Sachs Group reported 6.3 pct passive stake in co as of Dec. 31 - SEC filing

* The Goldman Sachs Group Inc reports 6.3 percent passive stake in Allergan Plc as of dec. 31, 2016 - sec filing Source text: (http://bit.ly/2knWz9s) Further company coverage: